Immunadd, Inc. news

Our team was awarded the 18th National Award in the Academic Research for “the Discovery of IA05 as a Novel Saponin Adjuvant for Therapeutic Vaccine.”

ImmunAdd, a privately held pharmaceutical company developing a fully synthetic, rationally designed, saponin-based small molecule vaccine adjuvant, attended the Vaccines Summit 2022 in Washington DC on October 11-13.

Founder of ImmunAdd, Pi-Hui Liang, said “My team and I were delighted to attend the Vaccines Summit, an internationally renowned academic conference, where we presented a poster describing our state-of-the art vaccine adjuvant IA-05 and our business development team

• ImmunAdd’s next-generation Saponin-based adjuvant IA-05 induced both humoral and cellular immunities in various vaccines, including those against COVID-19, influenza, and cancer.
• IA-05 is accessible via total chemical synthesis and does not rely on extracts from Quillaja Saponaria or any other tree.
• ImmunAdd is undertaking the development of IA-05 in collaboration with several biopharma from all over the world.

ImmunAdd, a privately held pharma